ABOUT THE DRUG INFORMATION ASSOCIATION (DIA)
With almost 20,000 members worldwide, the Drug Information Association (DIA) is the premier member-driven organization encompassing the full continuum of disciplines in the pharmaceutical and related industries. The mission of DIA is to serve and develop members by providing a neutral, global forum that promotes the exchange of information critical to their professional performance and achievement. The goal of DIA is to be the most effective means for members to obtain the knowledge they need to advance their career, their profession, and their organization.

ABOUT THE EUROPEAN FEDERATION OF PHARMACEUTICAL INDUSTRIES & ASSOCIATIONS (EFPIA)
EFPIA is the voice of the pharmaceutical industry in Europe. Through its membership, EFPIA represents 2,200 companies committed to researching, developing, and bringing to patients new medicines that improve health and quality of life around the world. The mission of EFPIA is to improve the competitiveness of the research-based pharmaceutical industry in Europe in a regulatory and political environment, which above all stimulates R&D and rewards innovation.

ABOUT THE SOUTHERN AFRICAN DEVELOPMENT COMMUNITY (SADC)
SADC consists of 15 Member States (approximately 200 million people): Angola, Botswana, the Democratic Republic of Congo, Lesotho, Madagascar, Malawi, Mauritius, Mozambique, Namibia, South Africa, Swaziland, United Republic of Tanzania, Zambia, Zimbabwe and Seychelles. SADC’s clear mission statement is “To promote sustainable and equitable economic growth and socio-economic development through efficient productive systems, deeper co-operation and integration, good governance, and durable peace and security, so that the region emerges as a competitive and effective player in international relations and the world economy”. This mission is anchored on the common values and principles and the historical and cultural affinities that exist between the people of Southern Africa.”

Conference Chairperson
Prof. Trevor M. Jones, CBE, Kings College London, UK; Recently WHO Commissioner CIPIH

Conference Co-chairperson
Mr. Joseph Mthetwa, Senior Programme Manager for Health and Pharmaceuticals, SADC Secretariat, Botswana

Programme Committee
Ms. Engela Dedwith, Eli Lilly, South Africa
Ms. Muriel Delalleau, Biogen Idec Limited, UK (EFPIA-IRAG ARN Deputy Lead)
Ms. Osaretn Jaiyeola, GlaxoSmithKline, Nigeria
Mr. Salieu Jalloh, Novartis Pharma AG, Switzerland
Mr. Igor Knezevic, Bayer Schering Pharma AG, Germany
Ms. Gina Partridge, Abbott Laboratories, South Africa
Mr. Niklaus Puppato, Hoffmann-La Roche Ltd, Switzerland
Ms. Florence Roizard, Merck Sharp & Dohme, France (EFPIA-IRAG ARN Lead)
Ms. Danielle Tobin, Pfizer Ltd, UK
Ms. Claire Tshilumba, Merck Sharp & Dohme, South Africa

Programme Advisors
Ms. Valérie Abondo, South Africa
Ms. Val Beaumont, Executive Director, Innovative Medicines South Africa (MSA)
Ms. Delese Mimi Darko, Head, Drug Evaluation & Registration, Food and Drugs Board, Ghana
Ms. Mandisa Hela, Registrar, Medicines Regulatory Agency, South Africa
Ms. Gugu N. Mahlangu, Director, Technical Services, Medicines Control Authority of Zimbabwe
Mr. Apollo E. Muhairwe, Executive Secretary/Registrar, National Drug Authority, Uganda
Ms. Esnart Mwape, Director, Technical Services, Medicines Regulatory Authority, Zambia
Ms. Kirti Narsai, Head, Scientific and Regulatory Affairs, Pharmaceutical Industry Association of South Africa (PIASA)
Dr. Lembit Rägo, Coordinator, Quality Assurance and Safety: Medicines (QSM), World Health Organization, Geneva, Switzerland

Simultaneous Translation will be available in English, French, and Portuguese

in collaboration with

Worldwide Headquarters
Drug Information Association, Inc.
800 Enterprise Road, Suite 200
Horsham, PA 19044, USA

Regional Offices
Basel, Switzerland  Tokyo, Japan  Mumbai, India  Beijing, China

To register, see page 5 or CLICK HERE.
For directions, see page 7 or CLICK HERE.
Background
This is the second DIA/SADC co-sponsored African Regulatory Conference in partnership with the Africa Regulatory Network (ARN). The ARN is an ad hoc regional network of EFPIA-International Regulatory Affairs Group (IRAG).

ARN works in partnership with regulatory authorities and the pharmaceutical industry in Africa to develop legislation and regulatory practices that enable patients to have access to good quality medicines, including innovative medicines.

Themes and Objectives
This 2nd African Regulatory Conference will focus on access for patients to safe, effective and quality medicines and it will offer the opportunity to:

- Foster collaboration between African Regulatory Authorities and the Pharmaceutical Industry
- Share information and best practices, and identify potential workable solutions which meet the needs of the Region
- Openly discuss issues facing African Regulatory Authorities and Industry

Presentations will be given by regional and international speakers, including Regulators. The format of the conference will include panel discussions to maximize contributions around the key topics.

Key Topics
- Regulatory Harmonisation: How Can It Improve Access to Medicines?
- The Value of Research and Development in Patient Access to Medicines
- How Do Changes in the Global Regulatory Environment Impact Africa?
- Regulatory Challenges to Patient Access to Medicines
  - Capacity Building
  - Speed to Market
  - Management of Variations
- Ensuring Patient Safety through Pharmacovigilance
- Ensuring Patient Safety through Product Quality Update, Including GMP, Site Inspections, and Anti-counterfeiting Strategies

Target Audience
Regulatory Affairs Professionals, Regulatory Authorities and other professionals involved in or interested in the aspects surrounding registration and control of medicinal products and regulatory harmonisation initiatives in the African region.

MONDAY, MARCH 1, 2010
18:00-20:00 REGISTRATION

DAY 1 | TUESDAY, MARCH 2, 2010
07:30-8:30 REGISTRATION AND WELCOME COFFEE

08:30-09:30 OPENING SESSION
Session Objective: Conference opening and statement of meeting objectives

INTRODUCTORY REMARKS
Prof. Trevor M. Jones, CBE
Kings College London, UK

Mr. Joseph Mthetwa
Senior Programme Manager for Healthcare and Pharmaceuticals, SADC Secretariat, Botswana

KEYNOTE ADDRESS:
Ms. Mandisa Hela
Registrar, Medicines Regulatory Agency, South Africa

WELCOME BY CO-SPONSORS AND PROGRAM COMMITTEE
DIA
Dr. Yves Juillet
Chair of Regulatory Policy and Technical Steering Committee at IFPMA, Senior Advisor, Les Entreprises de Médicament (LEEM), France

EFPIA/ARN
Ms. Engela Dedwith
Eli Lilly, South Africa, Area Regulatory Manager, AMEA/CIS-CEE (Non-EU)

09:30-13:00 SESSION 1
Regulatory Harmonization in Africa: Regional and Worldwide Organizations’ View, Key Opportunities and Challenges
Session Objective: The question of how ongoing regulatory harmonization initiatives in Africa can improve access to medicines will be discussed

Regulatory Harmonization and Public Health
Dr. Lembit Rägo
Coordinator, Quality Assurance and Safety: Medicines (QSM), World Health Organization, Geneva, Switzerland

New Partnership for Africa’s Development (NEPAD): The African Medicines Registration Harmonization (AMRH) Initiative
Prof Eric Buch
Health Adviser, NEPAD, Professor, Health Policy & Management, University of Pretoria, South Africa

10:30-11:00 COFFEE BREAK

Industry Perspective on the Harmonization and Regulatory Environment in Eastern & Central Africa
Dr. William Mwatu
Medical and Regulatory Director, GlaxoSmithKline, Kenya

Economic and Monetary Community of Central Africa Organization, Health Organisation
Mr Jean Jacques Moka
General Secretary, OCEAC, Cameroon

Dr. Emilienne Yissibi Pola
Coordinator, Central African Pharmaceutical Policy Harmonization Program, Cameroon
South African Development Community (SADC)
Mr. Joseph Mthetwa
Senior Programme Manager for Healthcare and Pharmaceuticals, SADC Secretariat, Botswana

East African Community (EAC)
Mr. Apollo Muhairwe
Executive Secretary/Registrar, National Drug Authority, Uganda

Panel Discussion:
Dr. Lembit Rägo - Coordinator, Quality Assurance and Safety: Medicines (QSM), World Health Organization, Geneva, Switzerland
Prof Eric Buch - Health Adviser, NEPAD, Professor, Health Policy & Management, University of Pretoria, South Africa
Mr. William Mwatu - Medical and Regulatory Director, GlaxoSmithKline, Kenya
Mr. Jean Jacques Moka - General Secretary, OCEAC, Cameroon
Dr. Emilienne Yissibi Pola - Coordinator, Central African Pharmaceutical Policy Harmonization Program, Cameroon
Mr. Joseph Mthetwa - Senior Programme Manager for Healthcare and Pharmaceuticals, SADC Secretariat, Botswana
Ms. Gugu N. Mahlangu - Director, Technical Services, Medicines Control Authority of Zimbabwe

13:00-14:00 LUNCH BREAK

14:00-15:00 SESSION 2
The Global Regulatory Environment & Opportunities for Africa
Session Objective: To raise awareness of changes in the global regulatory environment and their relevance for Africa.

ICH Update
Dr. Yves Juillet
Chair of Regulatory Policy and Technical Steering Committee at IFPMA, Senior Advisor, Les Entreprises du Médicament (LEEM), France

New EU Regulatory Trends
Transparency measures, Paediatric Regulations and Pharmacovigilance will be discussed

Dr. Truus Janse-de Hoog
Staff Member Medicines Evaluation Board, European Cluster; Chair of Coordination Group for Mutual Recognition and Decentralization Procedures - Human (CMD(h)), The Netherlands

Panel Discussion:
Dr. Yves Juillet - Chair of Regulatory Policy and Technical Steering Committee at IFPMA, Senior Advisor, Les Entreprises du Médicament (LEEM), France
Dr. Truus Janse-de Hoog - Staff Member Medicines Evaluation Board, European Cluster; Chair of Coordination Group for Mutual Recognition and Decentralization Procedures - Human (CMD(h)), The Netherlands
Dr. Lembit Rägo - Coordinator, Quality Assurance and Safety: Medicines (QSM), World Health Organization, Geneva, Switzerland
Ms. Kirti Narsai - Head, Scientific and Regulatory Affairs, Pharmaceutical Industry Association of South Africa (PIASA)

15:00-17:15 SESSION 3 - CONTINUED
The Role of Research and Development in Patient Access to New Medicines
Session Objective: Biological medicines and associated Regulatory features, as well as stimulation of R&D for neglected diseases will be discussed

Biological Medicines – Opportunities and Challenges
Dr Thomas Schreitmueller
Head of Biotech Analytics and Development, Roche, Switzerland

15:45-16:15 COFFEE BREAK

16:15-17:15 SESSION 3 - CONTINUED
R&D for Neglected Diseases
Dr. Arkadius Pichota
Preclinical Development, Novartis Institute for Tropical Diseases, Singapore

Panel Discussion:
Dr. Thomas Schreitmueller - Head of Biotech Analytics and Development, Roche, Switzerland
Dr. Arkadius Pichota - Preclinical Development, Novartis Institute for Tropical Diseases, Singapore
Ms. Val Beaumont - Executive Director, Innovative Medicines South Africa (IMSa)
Ms. Margareth Ndombo-Sigonda - NEPAD Health Pharmaceutical Coordinator
Professor Trevor M. Jones, CBE - Kings College London, UK

17:15-17:30 DAY 1 WRAP-UP
Prof. Trevor M. Jones, CBE
Kings College London, UK
Mr. Joseph Mthetwa
Senior Programme Manager for Healthcare and Pharmaceuticals, SADC Secretariat, Botswana

18:00 PRE-DINNER RECEPTION
19:00 CONFERENCE DINNER
(The dinner will be an additional fee and we kindly ask you to register in advance.)

DAY 2 | WEDNESDAY, MARCH 3, 2010
07:30-8:30 REGISTRATION AND WELCOME COFFEE
08:30-10:30 SESSION 4
Regulatory Challenges to Medicines Access
Session Objective: To review regulatory capacity, speed to market, and management of variations.

How Can Developing Countries Increase Regulatory Efficiency and Maintain Standards without Increasing Costs?
Mrs. Hauwa J. Keri
Director, Establishment Inspection, National Agency for Food and Drug Administration and Controls (NAFDAC), Nigeria

FDA Alumni Association’s International Network (FDAAA IN): Opportunity to Partner with National Regulatory Authorities
Dr. Ekopimo Ibia
Director, Global Medical and Regulatory Policy, Merck Research Laboratories, US
Evolving Legislation: the EU Management of Variations System  
Dr. Truus Janse-de Hoog  
Staff Member Medicines Evaluation Board, European Cluster; Chair of Coordination Group for Mutual Recognition and Decentralization Procedures - Human (CMD(h)), The Netherlands

The Management of Variations in Africa–Regulator View  
Ms. Delese Mimi Darko  
Head, Drug Evaluation & Registration, Food and Drug Board, Ghana

The Management of Variations in Africa–Industry Views and Key Issues  
Ms. Florence Roizard  
Director, Regulatory Affairs, Middle East and Africa, Merck Sharp & Dohme, France

Panel Discussion:  
Mrs. Hauwa J. Keri - Director, Establishment Inspection, National Agency for Food and Drug Administration and Controls (NAFDAC), Nigeria  
Dr. Ekopimo Ibia - Director, Global Medical and Regulatory Policy, Merck Research Laboratories, US  
Dr. Truus Janse-de Hoog - Staff Member Medicines Evaluation Board, European Cluster; Chair of Coordination Group for Mutual Recognition and Decentralization Procedures - Human (CMD(h)), The Netherlands  
Ms. Delese Mimi Darko - Head, Drug Evaluation & Registration, Food and Drug Board, Ghana  
Ms. Florence Roizard - Director, Regulatory Affairs, Middle East and Africa, Merck Sharp & Dohme, France  
Ms. Kirti Narsai - Head, Scientific and Regulatory Affairs, Pharmaceutical Industry Association of South Africa (PIASA)

10:30-11:00 COFFEE BREAK

11:00-12:30 SESSION 5  
Ensuring Patient Safety  
Session Objective: To discuss elements which contribute securing patient safety, including post-marketing surveillance

Establishing Pharmacovigilance Systems in Africa: Regulators’ Perspective  
Ms. Delese Mimi Darko  
Head, Drug Evaluation & Registration, Food and Drug Board, Ghana

Sharing and Managing Post-Marketing Safety Information  
Dr. Jayesh Pandit  
Head of Pharmacovigilance Department, Pharmacy & Poisons Board, Kenya

Post-marketing Surveillance and Bridge to Label Updates: An Industry Perspective  
Dr. Marta Gersberg  
Drug Safety, Sanofi-Aventis, France

Panel Discussion:  
Ms. Delese Mimi Darko - Head, Drug Evaluation & Registration, Food and Drug Board, Ghana  
Dr. Jayesh Pandit - Head of Pharmacovigilance Department, Pharmacy & Poisons Board, Kenya  
Dr. Marta Gersberg - Drug Safety, Sanofi-Aventis, France  
Ms. Esnat Mwape - Director General, Pharmaceutical Regulatory Authority, Zambia

12:30-13:30 LUNCH BREAK

13:30-16:30 SESSION 6  
Product Quality Update  
Session Objective: To discuss innovations in the Quality arena, GMP, Site Inspections and Anti-Counterfeiting Strategies

Update on Risk-Based GMP Site Inspections  
Mr. Deus K. Mubangizi  
Technical Officer, WHO Prequalification Program, World Health Organization Geneva, Switzerland

Update on WHO Initiatives Against Counterfeits  
Dr. Lembit Rägo  
Coordinator, Quality Assurance and Safety: Medicines (QSM), World Health Organization, Geneva, Switzerland

Global Industry Initiatives Update in Anti-counterfeiting Strategies  
Dr. Yves Juillet  
Chair of Regulatory Policy and Technical Steering Committee at IFPMA, Senior Advisor, Les Entreprises du Médicament (LEEM), France

15:00-15:30 COFFEE BREAK

15:30-16:30 SESSION 6 - CONTINUED  
Product Quality Update  
Regulators’ Strategies against Counterfeits: The Experience of Ivory Coast  
Dr. Parfait Kouassi  
President of Ivory Coast Pharmaceutical Association, Abidjan, Ivory Coast

Counterfeits: How Can Regulators Tackle the Issue in Africa?  
Mr. Griffith Molewa  
Manager Law Enforcement, Department of Health, South Africa

Panel Discussion:  
Mr. Deus K. Mubangizi - Technical Officer, WHO Prequalification Program, World Health Organization Geneva, Switzerland  
Dr. Lembit Rägo - Coordinator, Quality Assurance and Safety: Medicines (QSM), World Health Organization, Geneva, Switzerland  
Dr. Yves Juillet - Chair of Regulatory Policy and Technical Steering Committee at IFPMA, Senior Advisor, Les Entreprises du Médicament (LEEM), France  
Dr. Parfait Kouassi - President of Ivory Coast Pharmaceutical Association, Abidjan, Ivory Coast  
Mr. Griffith Molewa - Manager Law Enforcement, Department of Health, South Africa  
Ms. Esnat Mwape - Director General, Pharmaceutical Regulatory Authority, Zambia

16:30-17:00 CONFERENCE CLOSE  
Prof. Trevor M. Jones, CBE  
Kings College London, UK  
Mr. Joseph Mthetwa  
Senior Programme Manager for Healthcare and Pharmaceuticals, SADC Secretariat, Botswana

Unless otherwise disclosed, DIA acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organization they represent, or that of the Drug Information Association. Speakers and agenda are subject to change without notice. Recording of any DIA tutorial/workshop information in any type of media, is prohibited without prior written consent from DIA.
2nd African Regulatory Conference
March 2-3, 2010
The Misty Hills Country Hotel
Johannesburg, South Africa
In collaboration with:

Delegate Registration
Please return this form by 22nd February 2010 to:
Ripcord Promotions
Tel: +27(0)11 482 2835  Fax: +27(0) 866 161 575
Post: PO Box 91989 Auckland Park 2006  E-mail: dia@ripcord.za.com

For Office Use Only:
Date Rec’d:                                        Confirmation:                                 Payment Rec’d:                                  Event Pin:

Please complete in BLOCK CAPITALS and tick the appropriate blocks.

DELEGATE DETAILS
Delegate Type:
Surname First Names
Title (Mr/Ms/Dr) Preferred name for delegate badge
Company/Association
Position
Postal Address Code:
Office Tel Code: ( ) Fax: Code: ( )
E-mail Cellular
Special Dietary requirements: Vegetarian Halaal Other (specify):
Special Disability Needs (please specify)_________________________________ Emergency contact:____________________

REGISTRATION FEES
Early Bird registration discounts applicable only to registration forms received on/before 8th February 2010

Fees are inclusive of VAT at 14%.

<table>
<thead>
<tr>
<th></th>
<th>EARLY BIRD (RECEIVED BEFORE OR ON 8TH FEBRUARY 2010)</th>
<th>NORMAL (RECEIVED AFTER 8TH FEBRUARY 2010)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry International (Overseas)</td>
<td>R13,660</td>
<td>R15,200</td>
</tr>
<tr>
<td>Industry Regional (South Africa and other African Countries)</td>
<td>R 4,555</td>
<td>R 6,000</td>
</tr>
<tr>
<td>Non-Profit organization / Academic / Research Staff</td>
<td>R 3,035</td>
<td>R 4,500</td>
</tr>
<tr>
<td>Government</td>
<td>R1,515</td>
<td>R 2,500</td>
</tr>
<tr>
<td>Conference Dinner – Tuesday, 2nd March 2010</td>
<td>R265</td>
<td>R 300</td>
</tr>
<tr>
<td>TOTAL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**HOTEL ACCOMMODATION**

**Please note the following important points:**
- Accommodation will be allocated on a “first come first served” basis.
- Accommodation rates are subject to availability.
- Accommodation rates include breakfast, but exclude the 1% Tourism Levy on the accommodation portion of the rate. This will be charged as an extra to your hotel bill.
- At check-in, delegates will be required to provide a credit card imprint, or cash deposit, to secure the cost of extras.

<table>
<thead>
<tr>
<th>Single (1 Occupant)</th>
<th>Double (2 Occupants)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Misty Hills Country Hotel</td>
<td>Bed and Breakfast – R1175</td>
</tr>
</tbody>
</table>

Arrival Date: [ ]  Departure Date: [ ]  Sharing with: [ ]

Rate: [ ]  X  (no of nights)  = [ ]  

☐ Please add accommodation to my total invoice

☐ I wish to settle my accommodation directly with the hotel by credit card

**AIRPORT TRANSFERS**
- I wish to make use of the complimentary airport shuttle

ARRIVAL DATE: [ ]  ARRIVAL TIME: [ ]  FLIGHT NO: [ ]  ARRIVING FROM: [ ]

DEPARTURE DATE: [ ]  DEPARTURE TIME: [ ]  FLIGHT NO: [ ]  DEPARTING TO: [ ]

**CANCELLATIONS / AMENDMENTS**

All cancellations / amendments must be submitted in writing on or before Monday, 15th February 2010 and will be subject to a cancellation/amendment fee of R500 per registration. Cancellations received after 15 February 2010 will be subject to a cancellation fee of 50% of the full value of the registration. Cancellations received on or after 22 February 2010 will be subject to a cancellation fee of 100% of the full value of the registration.

**PAYMENT OPTIONS** (registration will only be confirmed upon receipt of payment)

NB: Invoice, DIA banking details and reference number will be sent upon receipt of registration form.

Please provide your VAT number if this is to reflect on the Tax Invoice: [ ]

☐ Direct Deposit

☐ Please debit my credit card: [ ] Visa [ ] Master [ ] Diners [ ] Amex

Credit Card number: [ ]

Name on Card: [ ]

Expiry Date: [ ] [ ] [ ] [ ]  CVV Code (Last 3 number on reverse side of card): [ ] [ ]

Payment Option: [ ] Straight [ ] Budget: [ ] Months  Amount: [ ]

Signature: ____________________________  Date: ____________________________

**PLEASE NOTE:** Credit card payments will be processed through the Red Balloon Credit Card Merchant and will appear on your statement as DIA African Regulatory Conference Manual transaction.

**PLEASE RETURN THIS FORM BY 22nd February 2010.** Late registrations will incur a R500 administration fee. Confirmation of registration, together with a Tax Invoice, will be sent to you on receipt of your registration. Should you not receive the above documents within 48 hours of registration, please contact Ripcord Promotions. Tel. (+2711) 482-2835, Fax 0866 161575 or e-mail dia@ripcord.za.com. When making a direct deposit, please ensure that your name and unique PIN number are reflected on the deposit slip/proof of payment, and forward same to Ripcord Promotions.

**RESPONSIBILITY**

The Committee of Drug Information Association 2010 (referred to as the “Conference”) will do everything possible to ensure that your attendance at the Conference will be as comfortable as possible. The Conference, any member or members of its committee and its appointed agents or sub-contractors, act on the basis that they attend to the arrangements of the Conference for the convenience of the Conference delegates. They perform all tasks on condition that the Conference, any member or members of its committee and its appointed agents or other sub-contractors cannot be held responsible for any loss, personal injury, damage or inconvenience (however arising) experienced by delegates of the Conference; neither can they be held responsible for unforeseen partial or total cancellation of the event for which no refunds can be guaranteed. The programme is subject to change without notice.

By forwarding the Registration Form I agree to the clauses in the Registration Form and I have noted the reservation and cancellation details.

Signature: ____________________________  Date: ____________________________
MISTY HILLS
COUNTRY HOTEL
CONFERENCE CENTRE & SPA

69 Drift Boulevard, Muldersdrift, 1747
Private Bag 1, Muldersdrift, 1747
Tel: 011 950 6000 / Fax 011 957 3212
Email: sales@rali.co.za
Website: www.rali.co.za

Map to Misty Hills

Directions

From OR Tambo International Airport take the Gillooly's intersection N1 highway to Sandton / Roodepoort

- Take the N1 highway to Roodepoort
- Take the Beyers Naude Off ramp and turn towards Honeydew
- The road becomes one lane in each direction, continue past Garden World
- After Garden World and Oakfield Farm, the road becomes 2 lanes again.
- Turn at the first road left into DRIFT BOULEVARD/MULDERSDRIFT (R114)
- The Hotel is about 800 meters on the right hand side.